MDGL · Company research

Madrigal Pharmaceuticals, Inc.

2 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

MilestoneMDGLMadrigalQ4 2026

Ervogastat/resmetirom drug-drug interaction study start, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Madrigal (Rezdiffra (resmetirom) + ervogastat for MASH combination): a step in the program rather than a decision or a data readout.

More details

Entry

Ervogastat/resmetirom drug-drug interaction study start · Company milestone

Drug

Rezdiffra (resmetirom) + ervogastat

For

MASH combination

Stage

Phase 1 · an early safety study in a small group of people

When

Q4 2026 · the company gave a window, not a day

Source note

From Madrigal's Q1 2026 results release (May 6, 2026). Madrigal's Q2 2026 release (Jul 30, 2026) gave no new dated milestones; MAESTRO-NASH OUTCOMES F4c readout remains 2027 (already listed).

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
MDGL headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsMDGLMadrigal2027

Madrigal expects to report results from its Phase 3 study of Rezdiffra (resmetirom) for Compensated MASH cirrhosis (F4c) during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details

Entry

MAESTRO-NASH OUTCOMES Phase 3 topline: Rezdiffra in compensated MASH cirrhosis (F4c) · Clinical trial results (readout / topline data)

Drug

Rezdiffra (resmetirom)

For

Compensated MASH cirrhosis (F4c)

Stage

Phase 3 · the last stage before a drug can be approved

When

2027 · the company gave a window, not a day

Source note

Q2 2026 press release (July 30, 2026): company expects the event-driven MAESTRO-NASH OUTCOMES study to read out in 2027, with events accruing in line with that timeframe. Success would add an F4c indication and support full approval in noncirrhotic MASH. Year-level precision only.

Checked

Checked by a person when it was added

Verify it

Source: globenewswire.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
MDGL headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

ApprovalMDGLMadrigalJun 3, 2026

UK regulators approved Madrigal’s Rezdiffra (resmetirom) for MASH (metabolic dysfunction-associated steatohepatitis) on Jun 3, 2026. The company can now sell it in that market.

More details

Entry

MHRA authorises Rezdiffra (resmetirom) for MASH in adults in Great Britain · Regulatory approval

Drug

Rezdiffra (resmetirom)

For

MASH (metabolic dysfunction-associated steatohepatitis)

Stage

Regulatory (MHRA marketing authorisation)

When

Jun 3, 2026

Source note

The UK's MHRA authorised resmetirom (Rezdiffra) for the treatment of adults with metabolic dysfunction-associated steatohepatitis, opening a second major ex-US market for Madrigal's lead product.

Checked

Checked by a person when it was added

Verify it

Source: gov.uk ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
Drugs@FDA ↗ — search the drug name for approval letters
MDGL headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ConferenceMDGLMadrigalMay 20, 2026

Madrigal presented data on Rezdiffra (resmetirom) for MASH / compensated MASH cirrhosis (F4c) at a medical meeting on May 20, 2026. The linked source has the details.

More details

Entry

Madrigal to present Phase 3 Rezdiffra analyses at EASL 2026 (May 27-30) · Data presented at a medical meeting

Drug

Rezdiffra (resmetirom)

For

MASH / compensated MASH cirrhosis (F4c)

Stage

Phase 3 · the last stage before a drug can be approved

When

May 20, 2026

Source note

Madrigal announced eight abstracts for EASL Congress 2026, including secondary analyses of the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials on lipid profiles and two-year compensated MASH cirrhosis (F4c) data on ANTICIPATE-NASH portal hypertension risk scores. This is the pre-announcement; the data were presented at the congress the following week.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
MDGL headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ApprovalMDGLMadrigalMar 14, 2024

The FDA approved Madrigal’s Rezdiffra (resmetirom) for NASH/MASH on Mar 14, 2024. The company can now sell it in that market.

More details

Entry

FDA approval of Rezdiffra: first NASH drug · Regulatory approval

Drug

Rezdiffra (resmetirom)

For

NASH/MASH

When

Mar 14, 2024

Checked

Checked by a person when it was added

Verify it

SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
Drugs@FDA ↗ — search the drug name for approval letters
MDGL headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsMDGLMadrigalDec 19, 2022

Madrigal reported results from its Phase 3 study of resmetirom for NASH/MASH on Dec 19, 2022. The linked source has what the numbers showed.

More details

Entry

MAESTRO-NASH topline: both primary endpoints met · Clinical trial results (readout / topline data)

Drug

resmetirom

For

NASH/MASH

Stage

Phase 3 · the last stage before a drug can be approved

When

Dec 19, 2022

Source note

First positive Phase 3 in NASH; resmetirom hit resolution and fibrosis endpoints.

Checked

Checked by a person when it was added

Verify it

SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
MDGL headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to MDGL.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.